Lifecore Biomedical, Inc. (LFCR)
(Delayed Data from NSDQ)
$5.88 USD
+0.20 (3.43%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $5.88 +0.01 (0.09%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth D Momentum D VGM
Lifecore Biomedical (LFCR) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$6.50 | $8.00 | $5.00 | 14.44% |
Price Target
Based on short-term price targets offered by two analysts, the average price target for Lifecore Biomedical comes to $6.50. The forecasts range from a low of $5.00 to a high of $8.00. The average price target represents an increase of 14.44% from the last closing price of $5.68.
Analyst Price Targets (2 )
Broker Rating
Lifecore Biomedical currently has an average brokerage recommendation (ABR) of 2.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by three brokerage firms. The current ABR compares to an ABR of 2.33 a month ago based on three recommendations.
Of the three recommendations deriving the current ABR, one is Strong Buy, representing 33.33% of all recommendations. A month ago, Strong Buy represented 33.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.33 | 2.33 | 2.33 | 2.33 | 2.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/5/2024 | Craig-Hallum | Matthew G Hewitt | Not Available | Strong Buy |
8/28/2024 | Barrington Research | Michael J Petusky | Strong Buy | Hold |
5/1/2024 | Stephens | Jacob Johnson | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.33 |
ABR (Last week) | 2.33 |
# of Recs in ABR | 3 |
Average Target Price | $6.50 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 89 of 252 |
Current Quarter EPS Est: | -0.27 |
LFCR FAQs
Lifecore Biomedical, Inc. (LFCR) currently has an average brokerage recommendation (ABR) of 2.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 3 brokerage firms.
The average price target for Lifecore Biomedical, Inc. (LFCR) is $6.50. The current on short-term price targets is based on 2 reports.
The forecasts for Lifecore Biomedical, Inc. (LFCR) range from a low of $5 to a high of $8. The average price target represents a increase of $10.54 from the last closing price of $5.88.
The current UPSIDE for Lifecore Biomedical, Inc. (LFCR) is 10.54%
Based on short-term price targets offered by two analysts, the average price target for Lifecore Biomedical comes to $6.50. The forecasts range from a low of $5.00 to a high of $8.00. The average price target represents an increase of 14.44% from the last closing price of $5.68.